Cargando…

Definitive and adjuvant radiotherapy for sinonasal squamous cell carcinomas: a single institutional experience

BACKGROUND: The aim of this study was to evaluate the disease outcomes of patients treated with definitive and adjuvant radiotherapy for squamous cell carcinomas of the nasal cavity and paranasal sinuses in a single institution. METHODS: Between 2007–2012 patients were retrospectively identified fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Duru Birgi, Sumerya, Teo, Mark, Dyker, Karen E., Sen, Mehmet, Prestwich, Robin J D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574072/
https://www.ncbi.nlm.nih.gov/pubmed/26377408
http://dx.doi.org/10.1186/s13014-015-0496-3
_version_ 1782390562779824128
author Duru Birgi, Sumerya
Teo, Mark
Dyker, Karen E.
Sen, Mehmet
Prestwich, Robin J D
author_facet Duru Birgi, Sumerya
Teo, Mark
Dyker, Karen E.
Sen, Mehmet
Prestwich, Robin J D
author_sort Duru Birgi, Sumerya
collection PubMed
description BACKGROUND: The aim of this study was to evaluate the disease outcomes of patients treated with definitive and adjuvant radiotherapy for squamous cell carcinomas of the nasal cavity and paranasal sinuses in a single institution. METHODS: Between 2007–2012 patients were retrospectively identified from electronic databases who had undergone surgery and adjuvant radiotherapy or definitive radiotherapy for sinonasal squamous cell carcinomas with curative intent. RESULTS: Fourty three patients with sinonasal squamous cell carcinoma were identified (22 nasal cavity, 21 paranasal sinuses). 31/43 (72 %) had T3 or T4 disease; nodal stage was N0 in 38, N1 in 4, Na/b in 0 and N2c in 1 patient. Median age was 67 years (range 41–86). 18 (42 %) received definitive and 25 (58 %) adjuvant radiotherapy. Radiotherapy was delivered using either conventional radiotherapy (n = 39) or intensity modulated radiotherapy (n = 4). Elective neck radiotherapy was delivered to two patients. Chemotherapy was delivered to 6/43 (14 %) of patients. Two-year local control, regional control, distant metastases free survival, progression free survival, cause specific survival and overall survival were 81 %, 90 %, 95 %, 71 %, 84 % and 80 % respectively. There was no significant difference in outcome comparing patients who underwent surgery and adjuvant radiotherapy with patients receiving definitive radiotherapy (2 year locoregional disease free survival 75 % and 70 % respectively, p = 0.98). Pooly differentiated tumours were significantly associated with inferior disease outcomes. Local, regional, combined local and regional, and distant failure occurred in 7 (16 %), 3 (7 %), 1 (2 %) and 2 (5 %) of patients; all 3 regional recurrences were in patients with nasal cavity squamous cell carcinomas who had not undergone elective neck treatment. CONCLUSIONS: Definitive or adjuvant radiotherapy provides an effective treatment for sinonasal malignancies. The main pattern of failure remains local, suggesting the need for investigation of intensified local therapy. Whilst remaining uncommon, the cases of regional failure mean that the merits of elective lymph node treatment should be considered on an individual basis.
format Online
Article
Text
id pubmed-4574072
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45740722015-09-19 Definitive and adjuvant radiotherapy for sinonasal squamous cell carcinomas: a single institutional experience Duru Birgi, Sumerya Teo, Mark Dyker, Karen E. Sen, Mehmet Prestwich, Robin J D Radiat Oncol Research BACKGROUND: The aim of this study was to evaluate the disease outcomes of patients treated with definitive and adjuvant radiotherapy for squamous cell carcinomas of the nasal cavity and paranasal sinuses in a single institution. METHODS: Between 2007–2012 patients were retrospectively identified from electronic databases who had undergone surgery and adjuvant radiotherapy or definitive radiotherapy for sinonasal squamous cell carcinomas with curative intent. RESULTS: Fourty three patients with sinonasal squamous cell carcinoma were identified (22 nasal cavity, 21 paranasal sinuses). 31/43 (72 %) had T3 or T4 disease; nodal stage was N0 in 38, N1 in 4, Na/b in 0 and N2c in 1 patient. Median age was 67 years (range 41–86). 18 (42 %) received definitive and 25 (58 %) adjuvant radiotherapy. Radiotherapy was delivered using either conventional radiotherapy (n = 39) or intensity modulated radiotherapy (n = 4). Elective neck radiotherapy was delivered to two patients. Chemotherapy was delivered to 6/43 (14 %) of patients. Two-year local control, regional control, distant metastases free survival, progression free survival, cause specific survival and overall survival were 81 %, 90 %, 95 %, 71 %, 84 % and 80 % respectively. There was no significant difference in outcome comparing patients who underwent surgery and adjuvant radiotherapy with patients receiving definitive radiotherapy (2 year locoregional disease free survival 75 % and 70 % respectively, p = 0.98). Pooly differentiated tumours were significantly associated with inferior disease outcomes. Local, regional, combined local and regional, and distant failure occurred in 7 (16 %), 3 (7 %), 1 (2 %) and 2 (5 %) of patients; all 3 regional recurrences were in patients with nasal cavity squamous cell carcinomas who had not undergone elective neck treatment. CONCLUSIONS: Definitive or adjuvant radiotherapy provides an effective treatment for sinonasal malignancies. The main pattern of failure remains local, suggesting the need for investigation of intensified local therapy. Whilst remaining uncommon, the cases of regional failure mean that the merits of elective lymph node treatment should be considered on an individual basis. BioMed Central 2015-09-17 /pmc/articles/PMC4574072/ /pubmed/26377408 http://dx.doi.org/10.1186/s13014-015-0496-3 Text en © Duru Birgi et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Duru Birgi, Sumerya
Teo, Mark
Dyker, Karen E.
Sen, Mehmet
Prestwich, Robin J D
Definitive and adjuvant radiotherapy for sinonasal squamous cell carcinomas: a single institutional experience
title Definitive and adjuvant radiotherapy for sinonasal squamous cell carcinomas: a single institutional experience
title_full Definitive and adjuvant radiotherapy for sinonasal squamous cell carcinomas: a single institutional experience
title_fullStr Definitive and adjuvant radiotherapy for sinonasal squamous cell carcinomas: a single institutional experience
title_full_unstemmed Definitive and adjuvant radiotherapy for sinonasal squamous cell carcinomas: a single institutional experience
title_short Definitive and adjuvant radiotherapy for sinonasal squamous cell carcinomas: a single institutional experience
title_sort definitive and adjuvant radiotherapy for sinonasal squamous cell carcinomas: a single institutional experience
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574072/
https://www.ncbi.nlm.nih.gov/pubmed/26377408
http://dx.doi.org/10.1186/s13014-015-0496-3
work_keys_str_mv AT durubirgisumerya definitiveandadjuvantradiotherapyforsinonasalsquamouscellcarcinomasasingleinstitutionalexperience
AT teomark definitiveandadjuvantradiotherapyforsinonasalsquamouscellcarcinomasasingleinstitutionalexperience
AT dykerkarene definitiveandadjuvantradiotherapyforsinonasalsquamouscellcarcinomasasingleinstitutionalexperience
AT senmehmet definitiveandadjuvantradiotherapyforsinonasalsquamouscellcarcinomasasingleinstitutionalexperience
AT prestwichrobinjd definitiveandadjuvantradiotherapyforsinonasalsquamouscellcarcinomasasingleinstitutionalexperience